Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer
Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer
复制标题
DOI：
10.1016/j.urolonc.2004.12.014
复制
发表时间：
2005-07-01
影响因子：
2.7
通讯作者：
Reichardt, JKV
中科院分区：
文献类型：
--
作者：
Salam, MT;Ursin, G;Reichardt, JKV
前列腺是雄激素依赖性的，雄激素合成基因类固醇5-α还原酶II型（SRD 5A 2）的多态性可能与良性前列腺增生（BPH）和前列腺癌相关。我们在多种族人群中评估了SRD 5A 2基因3种多态性（2种单核苷酸多态性：丙氨酸-49转苏氨酸[A49 T]和缬氨酸-89转亮氨酸[V89 L]，以及3'非翻译区的（TA）（n）二核苷酸重复序列）与BPH和前列腺癌之间的关联。从年度前列腺癌筛查项目和大型泌尿科诊所招募了60至86岁的男性。非条件Logistic回归用于计算比值比（OR）和95%置信区间（95%CI）。我们对606名男性（412名西班牙裔，98名高加索人，73名非洲裔美国人和23名亚洲人）进行了基因分型，其中100名患有前列腺癌，393名患有BPH（280名有症状，113名无症状），113名前列腺正常。总体而言，V89 L变异与前列腺癌相关;亮氨酸-亮氨酸（LL）基因型男性与缬氨酸-缬氨酸（VV）基因型男性相比的OR为4.47（95%CI，1.24-16.18）。这种关联在西班牙裔中更强（OR = 7.26; 95%CI：1.49-35.47）。虽然V89 L与总人群中的BPH无显著相关性，但在西班牙裔人群中，BPH风险随L等位基因数量的增加而显著增加（趋势P = 0.03）。前列腺癌和BPH与丙氨酸49-苏氨酸单核苷酸多态性和（TA）（n）重复无关。这些结果表明，SRD 5A 2基因可能在BPH和前列腺癌中发挥重要作用。(c)2005年爱思唯尔公司All rights reserved.
The prostate gland is an androgen-dependent, and polymorphisms in androgen synthesis gene steroid 5-alpha reductase type II (SRD5A2) may be associated with benign prostatic hyperplasia (BPH) and prostate cancer. We evaluated the association between 3 polymorphisms in the SRD5A2 gene (2 single nucleotide polymorphism: alanine-49 to threonine [A49T] and valine-89 to leucine [V89L], and a (TA)(n) dinucleotide repeat in the 3' untranslated region), and BPH and prostate cancer within a multiethnic population. Men between 60 and 86 years of age were recruited from annual prostate cancer screening programs and from a large urology clinic. Unconditional logistic regression was used to compute odds ratios (OR) and 95% confidence intervals (95% CI). We genotyped 606 men (412 Hispanic, 98 Caucasian, 73 African-American, and 23 Asian), of whom 100 had prostate cancer, 393 had BPH (280 symptomatic and 113 asymptomatic), and 113 had normal prostates. Overall, the V89L variant was associated with prostate cancer; the OR for men with the leucine-leucine (LL) genotype compared to men with the valine-valine (VV) genotype was 4.47 (95% CI, 1.24-16.18). This association was stronger in Hispanics (OR = 7.26; 95% CI: 1.49-35.47). Although V89L was nonsignificantly associated with BPH in overall population, BPH risk increased significantly with the number of L alleles in Hispanics (P for trend = 0.03). Prostate cancer and BPH were not associated with the alanine-49 to threonine single nucleotide polymorphism and the (TA)(n) repeat. These results suggest that the SRD5A2 gene may play an important role in both BPH and prostate cancer. (c) 2005 Elsevier Inc. All rights reserved.